Investors Rally for Class Action Against Applied Therapeutics

Investors Encourage Legal Action Against Applied Therapeutics

Recently, a group of investors interested in Applied Therapeutics, Inc. (NASDAQ: APLT) found themselves at a crossroads as significant losses prompted them to consider banding together for legal recourse. The announcement from Robbins Geller Rudman & Dowd LLP serves as a clarion call for those who acquired APLT securities between January 3, 2024, and December 2, 2024, to consider stepping up as lead plaintiffs in a new class action lawsuit.

The Opportunity to Lead in the Class Action

The class action lawsuit, titled Alexandru v. Applied Therapeutics, Inc., No. 24-cv-09715 (S.D.N.Y.), alleges serious violations of the Securities Exchange Act of 1934. Investors who experienced substantial financial losses during this period have a unique opportunity to seek appointment as lead plaintiffs and take action against the company for its alleged misleading statements and failure to follow clinical protocols.

Details Surrounding the Class Action Lawsuit

The complaint highlights major concerns about Applied Therapeutics' adherence to trial protocols. On January 3, 2024, the firm announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for govorestat, aiming to treat Classic Galactosemia. However, the class action accuses defendants of knowingly misrepresenting the company’s adherence to regulatory standards, thus hiding the potential for the NDA to be rejected.

Exposing the Risks of Misrepresentation

The stakes became even clearer with a significant reveal on November 27, 2024, when the FDA delivered a Complete Response Letter regarding the NDA, indicating that it could not be approved in its current form due to various deficiencies. Following this disclosure, the price of APLT shares plummeted by over 80% across three trading sessions, showcasing the severe impact of these allegations on investors.

Further Complications Highlighted

The situation worsened when, on December 2, 2024, Applied Therapeutics publicly admitted to receiving an FDA warning. The issues cited included problems with electronic data capture and a dosing error during the clinical study phase. This added complexity led to another significant drop of more than 26% in share prices over the following days, indicating that investors faced a catastrophic impact on their holdings.

Understanding the Lead Plaintiff Process

Under the Private Securities Litigation Reform Act of 1995, any investor who purchased APLT securities during the defined class period has the right to pursue being appointed as a lead plaintiff in the class action. Lead plaintiffs will represent the interests of all class members, utilizing the guidance of their chosen legal representation. Importantly, individual investors’ chances for sharing in potential recoveries remain intact regardless of whether they do take on this leadership role.

The Role of Robbins Geller Rudman & Dowd LLP

Robbins Geller is recognized as one of the top law firms fighting for investor rights. With an impressive history of securing substantial settlements in securities fraud cases, the firm has a proven track record of representing victims effectively. They have successfully recovered over $6.6 billion for investors, reinforcing their position as a formidable ally in navigating complex legal battles. Investors considering participation in the class action can reach out to J.C. Sanchez or Jennifer N. Caringal for assistance in understanding their options.

Contact Details for Further Assistance

For inquiries, contact Robbins Geller at 800-449-4900 or via email at info@rgrdlaw.com. Those interested in joining the class action or needing more information should not hesitate to engage with the experienced team.

Frequently Asked Questions

What is the class action lawsuit about?

The lawsuit against Applied Therapeutics involves allegations of misleading statements and violations of the Securities Exchange Act related to their New Drug Application process.

Who is eligible to be a lead plaintiff?

Any investor who purchased APLT securities during the defined class period is eligible to seek appointment as lead plaintiff in the lawsuit.

What happened to APLT's stock price?

After the FDA's response regarding the NDA and subsequent disclosures, APLT's stock experienced significant declines, dropping over 80% and later more than 26% in rapid succession.

How can investors get involved?

Investors can reach out to Robbins Geller for guidance on how to participate in the class action and possibly become a lead plaintiff.

What services does Robbins Geller offer?

Robbins Geller provides legal support and representation for investors in securities fraud cases, helping them secure a fair outcome for their losses.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.